Ensysce Biosciences ENSC
NASDAQ ENSC
$0.52 +0.02 (+4.29%)
At close: Oct 21, 2026 · 4:00 PM EDT

Ensysce Biosciences (ENSC) Preferred Stock Liabilities (2019 - 2020)

Updated

Ensysce Biosciences (ENSC) reported Preferred Stock Liabilities of $52,935 for Q4 2020, down 100.0% from $181.17 million a year earlier and down 80.5% from the prior quarter.

Analysis

Ensysce Biosciences (ENSC) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends

Dating back to Q4 2019, Ensysce Biosciences' Preferred Stock Liabilities record includes 5 quarters.

  • By year, Preferred Stock Liabilities came in at $181.17 million in FY2019.
  • Five-year quarterly Preferred Stock Liabilities spans a low of $52,179 in Q2 2020 and a high of $181.17 million in Q4 2019.
  • Per Business Quant data, the three quarters before Q4 2020 came in at $270,999 (Q3 2020), $52,179 (Q2 2020) and $4.54 million (Q1 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Ensysce Biosciences 1.35 Mn -9.90 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 52,935.00
Sep 30, 2020 270,999.00
Jun 30, 2020 52,179.00
Mar 31, 2020 4.54 Mn
Dec 31, 2019 181.17 Mn
API Access

Ensysce Biosciences Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ENSC&period=max&api_key=YOUR_API_KEY